Zentalis Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZNTL research report →
Range $5 – $10
Price Chart
About the company
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations.
- CEO
- Julia Marie Eastland
- IPO
- 2020
- Employees
- 106
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on ZNTL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $190.07M
- P/E
- -1.09
- PEG
- 0.04
- P/S
- 0.00
- P/B
- 1.31
- EV/EBITDA
- -1.17
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -87.95%
- ROIC
- -105.17%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0-100.0%
- Op Income
- $-152,808,000
- Net Income
- $-137,060,000+17.4%
- EPS
- $-1.91+18.0%
- OCF Growth
- +26.7%
- FCF Growth
- +26.8%
- 52W High
- $6.95
- 52W Low
- $1.21
- 50D MA
- $3.72
- 200D MA
- $3.42
- Beta
- 1.94
- RSI (14)
- 35
- Avg Volume
- 1.21M
No earnings-call transcripts are available for ZNTL yet.
- Free Float
- 68.2%
- Shares Outstanding
- 71.19M
- Float Shares
- 48.56M
of shares held by institutions
104 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| 5am Venture Management, LLC | 3.95M | 0 |
| Blackrock, Inc. | 3.75M | ▲ 2.48M |
| Squadron Capital Management LLC | 3.70M | ▲ 3.30M |
| Two Sigma Investments, LP | 3.02M | ▲ 68.41K |
| Vanguard Group Inc | 2.86M | ▼ 48.81K |
| Vanguard Capital Management LLC | 2.84M | ▲ 524.96K |
| Acadian Asset Management LLC | 2.68M | ▼ 166.35K |
| Citadel Advisors LLC | 2.30M | ▲ 566.32K |
| Renaissance Technologies LLC | 1.61M | ▼ 329.07K |
| Two Sigma Advisers, LP | 1.48M | ▲ 22.30K |
| Opaleye Management Inc. | 1.41M | 0 |
| Orbimed Advisors LLC | 1.39M | ▲ 1.39M |
Held by 102 ETFs
Biggest fund positions in ZNTL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 30, 26 | Bruns Ingmar | other | 9,727 |
| Aug 14, 26 | WALTERS GROUP | buy | 4,335,000 |
| Jun 16, 26 | Johnson David Michael | other | 57,100 |
| Jun 16, 26 | Skvarka Jan | other | 57,100 |
| Jun 16, 26 | Walker Luke Nathaniel | other | 57,100 |
| Jun 16, 26 | Kariuki Enoch | other | 57,100 |
| Jun 16, 26 | Myers Scott Dunseth | other | 57,100 |
| May 26, 26 | Campbell Shannon | other | 114,200 |
| May 22, 26 | Campbell Shannon | other | 0 |
| Feb 6, 26 | Bruns Ingmar | sell | 2,962 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ZNTL coverage
Recent articles, reports, and earnings notes.
No research on ZNTL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ZNTL report →Comparing Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Redhill Biopharma (NASDAQ:RDHL)
defenseworld.net · Oct 6
Leerink Partners Initiates Coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL)
defenseworld.net · Oct 5
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Oct 1
This Small Biotech's Cancer Drug Could Reach $1.3 Billion In Peak Sales
benzinga.com · Sep 16
Zentalis Pharmaceuticals, Inc. (ZNTL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com · Sep 14
BlackRock Inc. Invests $18.20 Million in Zentalis Pharmaceuticals, Inc. $ZNTL
defenseworld.net · Sep 4
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
globenewswire.com · Sep 2
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Sep 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.